Our medicines
We are a global biopharmaceutical company focused on advancing our mission and our business to help people in need of transformational medicines. In 2023, we invested $9.3 billion in R&D, which included the discovery and development of new medicines that help patients prevail over serious diseases.
Report side effects or product quality complaints
Report side effects or product quality complaints about legacy celgene products (ABRAXANE®, IDHIFA®, INREBIC®, ISTODAX®, POMALYST®, REBLOZYL®, REVLIMID®, THALOMID®, VIDAZA®)
Below is a list of our company's marketed products. Any linked documents and websites are intended only for U.S. residents 18 years or older, as the availability of medicines and the indications for which they are approved can vary with country and region.
Legacy brands
Prescribing information
Please click below to see the full U.S. Prescribing Information, including Boxed WARNING and Medication Guide/Patient Information for:
| ABECMA® | Medication guide | Prescribing information |
| ABRAXANE® | Patient information | Prescribing information |
| BREYANZI® | Medication guide | Prescribing information |
| BARACLUDE® | Patient information | Prescribing information |
| CAMZYOS® | Prescribing information | |
| COBENFY(TM) | Patient information | Prescribing information |
| DROXIA® | Prescribing information | |
| ELIQUIS® | Medication guide | Prescribing information |
| IDHIFA® | Patient information | Prescribing information |
| INREBIC® | Patient information | Prescribing information |
| KRAZATI® | Patient information | Prescribing information |
| OPDIVO®(nivolumab) | Medication guide | Prescribing information |
| OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) | Medication guide | Prescribing information |
| POMALYST® | Patient information | Prescribing information |
| REVLIMID® | Patient information | Prescribing information |
| THALOMID® | Patient information | Prescribing information |
| NULOJIX® | Medication guide | Prescribing information |
| YERVOY® | Medication guide | Prescribing information |